Want to see CYRX full AI Analyst Report?
Top Page
CryoPort
(NASDAQ:CYRX)
Select Model
Select Model
Rating:52Neutral
Price Target:
$17.00
▲(84.58% Upside)
Action:Reiterated
Date:08/07/26
CYRX scores in the low-to-mid range primarily due to weak TTM profitability and still-negative free cash flow despite rapid revenue growth and a manageable leverage profile. The latest earnings call supports improving operating trajectory (better EBITDA and operating cash flow) but maintains cautious guidance amid macro uncertainty. Technicals are a drag given weak near-term momentum, while valuation is a modest offset with a relatively low P/E.
Positive Factors
Life-science services growth and market reach
Strong growth in higher-value services and broad trial coverage reinforce Cryoport’s position in temperature-sensitive life-science logistics. As programs advance from clinical development to commercialization, this installed network can support recurring shipment and service demand.
Negative Factors
Persistent TTM losses
Despite revenue growth, the company remains unprofitable on a trailing basis, showing that scale has not yet translated into dependable earnings. Continued losses could constrain reinvestment, weaken equity returns and increase execution pressure on new initiatives.
Read all positive and negative factors
Positive Factors
Negative Factors
Life-science services growth and market reach
Strong growth in higher-value services and broad trial coverage reinforce Cryoport’s position in temperature-sensitive life-science logistics. As programs advance from clinical development to commercialization, this installed network can support recurring shipment and service demand.
Read all positive factors
CryoPort Key Performance Indicators (KPIs)
Any
Revenue by Geography
Breaks down sales across regions to reveal geographic strengths and concentration risks, indicating where the company is expanding, which markets drive growth, and where regulatory or economic changes could affect future revenue.
Breaks down sales across regions to reveal geographic strengths and concentration risks, indicating where the company is expanding, which markets drive growth, and where regulatory or economic changes could affect future revenue.
Data provided by:
The Fly
The FlyCryoPort (CYRX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$846.35M
Dividend YieldN/A
Average Volume (3M)690.07K
Price to Earnings (P/E)―
Beta (1Y)1.30
Revenue Growth-8.01%
EPS Growth17.42%
CountryUS
Employees688
SectorIndustrials
Sector Strength72
IndustryIntegrated Freight & Logistics
Share Statistics
EPS (TTM)-0.82
Shares Outstanding50,649,100
10 Day Avg. Volume860,552
30 Day Avg. Volume690,069
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)0.96
Price to Sales (P/S)2.73
P/FCF Ratio-17.12
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$19.00Price Target Upside106.30% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.78
Revenue Forecast (FY)$194.34M
CryoPort Business Overview & Revenue Model
Company Description
Cryoport, Inc. operates as a specialized service provider within the life sciences sector, delivering global temperature-controlled supply chain solutions across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region. Central t...
How the Company Makes Money
Cryoport primarily makes money by selling specialized temperature-controlled logistics and related supply chain services to biopharmaceutical and life sciences customers that need compliant, validated transport and handling for sensitive biologica...
CryoPort Earnings Call Summary
Earnings Call Date:Aug 06, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Nov 11, 2026
Earnings Call Sentiment Positive
The call communicated solid operational and financial progress: revenue growth (total and segment-level), expansion of clinical and commercial support, positive adjusted EBITDA and improved operating cash flow, product launches and facility expansions, and active digital/AI initiatives. Headwinds were largely cautious and strategic rather than acute — management reiterated guidance due to macro/geopolitical uncertainty, product growth is moderating YTD, China contribution remains small, and newer offerings like IntegriCell will take time to scale. On balance, the positive metrics and milestones outweigh the cautions, but the company remains prudent in guidance and execution timelines.Positive Updates
Total Revenue and Life Science Services Growth
Total revenue of $49.0 million in Q2 2026; Life Science Services revenue grew 15% year-over-year and represented 57% of total revenue, with biostorage and bioservices driving a 25% year-over-year increase.
Negative Updates
Conservative Guidance Despite Upside
Company reiterated full-year guidance despite a Q2 beat and strong H1 performance; management cited geopolitical and macroeconomic uncertainties as the rationale for maintaining the $192M–$196M range.
Read all updates
Q2-2026 Updates
Positive
Negative
Total Revenue and Life Science Services Growth
Total revenue of $49.0 million in Q2 2026; Life Science Services revenue grew 15% year-over-year and represented 57% of total revenue, with biostorage and bioservices driving a 25% year-over-year increase.
Read all positive updates
Company Guidance
Cryoport reaffirmed its full‑year 2026 revenue guidance of $192 million to $196 million despite a stronger-than-expected first half (roughly $97 million) and a $49 million Q2, citing geopolitical and macroeconomic uncertainties as reasons to maintain a prudent outlook; for the balance of 2026 management expects 11 possible BLA/MAA filings, five additional new therapy approvals and one additional label/geographic expansion. Key operating metrics underpinning the guidance include Life Science Services representing 57% of revenue and growing 15% year‑over‑year (biostorage and bioservices +25%), $9.4 million of commercial cell & gene therapy revenue (+9%) with the services portion +26%, $13.4 million from clinical-trial support (+12%), 22 commercial therapies supported, 779 total clinical trials (net +51 YoY) with 94 in Phase III and ~70% industry coverage. The company also noted improvements in profitability and liquidity—adjusted EBITDA from continuing operations improved $1.3 million year‑over‑year to a positive $0.4 million for the quarter, and operating cash flow was approximately +$5 million in H1 (a $17 million improvement vs. H1 2025)—while product trends (MVE) were mixed, with products flat year‑to‑date but Q2 product revenue up 7% and China representing roughly 2–3% of total revenue.CryoPort Financial Statement Overview
Summary
Income Statement
44
Neutral
Balance Sheet
63
Positive
Cash Flow
38
Negative
| Breakdown | TTM | Dec 2025 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 186.45M | 176.18M | 233.25M | 237.28M | 222.61M | 222.61M |
| Gross Profit | 87.77M | 83.05M | 99.33M | 103.87M | 96.58M | 96.58M |
| EBITDA | -3.13M | -2.10M | -66.36M | -6.19M | -248.91M | -248.91M |
| Net Income | -36.27M | 78.30M | -99.59M | -37.33M | -275.53M | -275.53M |
Balance Sheet | ||||||
| Total Assets | 756.20M | 764.99M | 703.49M | 957.74M | 1.04B | 1.11B |
| Cash, Cash Equivalents and Short-Term Investments | 396.69M | 411.21M | 261.75M | 456.75M | 523.32M | 628.80M |
| Total Debt | 232.02M | 230.72M | 250.70M | 416.00M | 435.91M | 427.06M |
| Total Liabilities | 265.50M | 262.35M | 301.59M | 468.72M | 482.91M | 471.14M |
| Stockholders Equity | 490.70M | 502.64M | 401.90M | 489.02M | 555.84M | 641.83M |
Cash Flow | ||||||
| Free Cash Flow | -20.34M | -28.09M | -33.58M | -45.66M | -26.05M | -16.88M |
| Operating Cash Flow | 7.97M | -8.58M | -16.32M | -757.00K | -1.85M | 8.13M |
| Investing Cash Flow | 27.27M | 250.32M | 176.81M | 36.05M | -59.68M | -469.25M |
| Financing Cash Flow | -4.28M | -21.07M | -161.53M | -23.80M | -39.17M | 564.34M |
CryoPort Technical Analysis
Positive
9.21
Price Trends
15.43
Positive
13.71
Positive
11.42
Positive
Market Momentum
0.11
Negative
64.41
Neutral
84.40
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CYRX, the sentiment is Positive. The current price of 9.21 is below the 20-day moving average (MA) of 15.26, below the 50-day MA of 15.43, and below the 200-day MA of 11.42, indicating a bullish trend. The MACD of 0.11 indicates Negative momentum. The RSI at 64.41 is Neutral, neither overbought nor oversold. The STOCH value of 84.40 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CYRX.
CryoPort Risk Analysis
CryoPort disclosed 33 risk factors in its most recent earnings report. CryoPort reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
CryoPort Peers Comparison
UnderperformOutperform
Sector (63)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | $25.78B | 39.13 | 18.75% | 0.62% | 5.28% | 28.24% | |
69 Neutral | $77.13B | 17.71 | 15.11% | 1.50% | 7.73% | 10.07% | |
68 Neutral | $15.85B | 11.10 | 15.95% | 2.89% | 20.89% | 25.35% | |
67 Neutral | $23.05B | 57.65 | 21.57% | ― | 7.03% | 16.37% | |
63 Neutral | $10.79B | 15.43 | 7.44% | 2.01% | 2.89% | -14.66% | |
54 Neutral | $5.20B | 39.59 | 4.41% | ― | 7.55% | 114.56% | |
52 Neutral | $846.35M | -20.89 | -7.25% | ― | -8.01% | 17.42% |
* Industrials Sector Average
CYRX
CryoPort
17.13
8.16
90.97%
XPO
XPO
197.74
60.34
43.92%
FDX
FedEx
325.08
138.04
73.80%
JBHT
JB Hunt
275.45
126.53
84.96%
ZTO
ZTO Express
21.37
2.84
15.34%
GXO
GXO Logistics
45.72
-8.87
-16.25%
CryoPort Corporate Events
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
Cryoport Shareholders Back Board, Auditor and Equity Plan
Positive
Jun 9, 2026
At its annual meeting on June 5, 2026, Cryoport, Inc. shareholders elected six directors, including Linda Baddour and CEO Jerrell W. Shelton, to serve until the 2027 meeting, reaffirming the company’s current board leadership. Investors also...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.